ライフサイエンスコーパス: pharmacogenetic

1 mechanism of action will lead to advances in pharmacogenetics.

2 l implementation of clopidogrel and warfarin pharmacogenetics.

3 edicine, and future clinical implications of pharmacogenetics.

4 obehavioral mechanisms of naltrexone and its pharmacogenetics.

5 could link to normal reversal learning using pharmacogenetics.

6 foods remain to be evaluated in light of CYP pharmacogenetics.

7 h particular design features of relevance in pharmacogenetics.

8 tcomes, which are of particular relevance in pharmacogenetics.

9 ashion, and by combining this with selective pharmacogenetic activation and optogenetic mapping techn

10 ns to ambient temperature changes, and their pharmacogenetic activation drives robust suppression of

11 Pharmacogenetic activation of c-Fos-labelled sleep-activ

12 Recently, we demonstrated that selective pharmacogenetic activation of CA neuron subpopulations i

13 periment, we examined the effect of repeated pharmacogenetic activation of CA neurons in the A1/C1 ce

14 Pharmacogenetic activation of Gq-GPCR signaling in senso

15 Pharmacogenetic activation of Mrgprb4-expressing neurons

16 Pharmacogenetic activation of noradrenergic neurons in t

17 Moreover, pharmacogenetic activation of Nos1(PVH) neurons suppress

18 changes of L5 PNs are prevented by selective pharmacogenetic activation of PV+INs in the barrel corte

19 Pharmacogenetic activation of somatostatin-expressing ce

20 Pharmacogenetic activation of the mouse CT equivalent ha

21 Furthermore, pharmacogenetic activation of these neurons using design

22 Furthermore, we developed a new pharmacogenetic algorithm that permits the stratificatio

23 d Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individ

24 Pharmacogenetic algorithms based on regression equations

25 demonstrate that racially informed warfarin pharmacogenetic algorithms perform better than tradition

26 conducting 1000 simulations of the applying pharmacogenetic algorithms to individualize dosing of wa

27 eclinical trial design of target population, pharmacogenetic algorithms, and dosing protocols to opti

28 This study evaluated the largest pharmacogenetic AMD cohort reported to date.

29 We used large-scale tissue profiling and pharmacogenetic analyses to identify deregulated signali

30 Pharmacogenetic analysis in the placebo controlled trial

31 The authors performed a pharmacogenetic analysis of antipsychotic treatment resp

32 This study is a pharmacogenetic analysis of the effects of genetic varia

33 Pharmacogenetics analysis showed single nucleotide polym

34 Pharmacogenetics analysis showed that exm-rs1321744 achi

35 Of these, 15 genetic, 2 pharmacogenetic and 6 biochemical studies were included

36 lysis of candidate gene association studies, pharmacogenetic and biochemical (metabolomics) studies p

37 we found that there were not enough genetic, pharmacogenetic and biochemical studies of ADHD in adult

38 Ca(2)(+) and glutamate indicators as well as pharmacogenetic and electrical control of neurotransmitt

39 Pharmacological, pharmacogenetic and environmental approaches to prevent

40 on of neuronal CB2Rs, as shown by a combined pharmacogenetic and immunohistochemical approach.

41 sleep-wake regulation in humans and combined pharmacogenetic and neurophysiologic methods to analyze

42 in the time in therapeutic range between the pharmacogenetic and standard arm (78.8% versus 73.8%; P=

43 or candidate gene association studies, 5 for pharmacogenetics and 21 for biochemical studies.

44 ncluding histocompatibility, immunogenetics, pharmacogenetics and anthropology studies, among many ot

45 This review will focus on pharmacogenetics and pharmacogenomics and their role in

46 f AA in patients treated with TNF inhibitors.Pharmacogenetics and the inherent physiologic levels of

47 First, using pharmacogenetics and two-photon calcium imaging, we vali

48 Pharmacogenetics and, more recently, pharmacogenomics ha

49 clinical pharmacology, pharmacokinetics and pharmacogenetics, and biostatistics and a patient repres

50 n microscopy, morphological reconstructions, pharmacogenetics, and diffusible dye, calcium, and gluta

51 ate with advances in genetics, genomics, and pharmacogenetics; and how they can apply this knowledge

52 Therefore, we used a pharmacogenetic approach based on a virus-mediated expre

53 ulation of sleep/wakefulness and highlight a pharmacogenetic approach for the amelioration of narcole

54 d, we evaluated the feasibility of a reverse pharmacogenetic approach in a preclinical mouse model.

55 We used a pharmacogenetic approach in mice to diminish MD neuron a

56 we bypass this lethality using a noninvasive pharmacogenetic approach to inducibly perturb neuron act

57 Using a pharmacogenetic approach to model MD hypofunction, we re

58 Thus, a pharmacogenetic approach to selective activation of key

59 eptor exclusively activated by designer drug pharmacogenetic approach, transient inhibition of MeA PT

60 Using a pharmacogenetic approach, we find PKMzeta-antisense in h

61 Using a pharmacogenetic approach, we find that mTOR-dependent ph

62 lbumin interneurons in the mPFC with a novel pharmacogenetic approach, we restored gamma-aminobutyric

63 Using a pharmacogenetic approach, we show that the predicted Dro

64 eptor exclusively activated by designer drug pharmacogenetic approach.

65 between correlation and causality, we used a pharmacogenetic approach.

66 A pharmacogenetics approach demonstrates that both glutama

67 This study's pharmacogenetics approach strongly implicates the role o

68 ethodologically, these results highlight how pharmacogenetic approaches allow neuron function to be q

69 Here, we used two pharmacogenetic approaches in transgenic mice to selecti

70 In the near future, pharmacogenetic approaches may facilitate personalized p

71 tions of molecular genetic, optogenetic, and pharmacogenetic approaches that overcome previous limita

72 ults highlight the requirement for stringent pharmacogenetic approaches to separate specific on-targe

73 Optogenetic and pharmacogenetic approaches were used to bidirectionally

74 ur findings advance the understanding of the pharmacogenetic architecture of statin response.

75 REVIEW: The fields of clinical genetics and pharmacogenetics are rapidly expanding.

76 70.6% and 72.2% (P=0.47) in the standard and pharmacogenetic arms, respectively.

77 results highlight the relevance of studying pharmacogenetics associated with efficacy and safety of

78 We identified a significant pharmacogenetic association at SNP rs37972, replicated i

79 The CATT and IVAN data do not support a pharmacogenetic association between the 2 VEGFR2 SNPs, r

80 A previously published study demonstrated a pharmacogenetic association between the minor alleles of

81 anisms and the clinical implications of this pharmacogenetic association remain unknown.

82 With the rapid emergence of pharmacogenetic association studies of single nucleotide

83 Pharmacogenetic association with anti-VEGF treatments ma

84 This study provides evidence that no pharmacogenetic associations exist between the studied V

85 Numerous pharmacogenetic associations have been discovered for im

86 unctional variants in GALR1 and to replicate pharmacogenetic associations is warranted.

87 The objectives were to replicate 3 reported pharmacogenetic associations of response in nAMD and to

88 We investigated pharmacogenetic associations of the previously studied G

89 This review highlights the germline pharmacogenetic associations that are currently being us

90 We estimated pharmacogenetic associations using high-quality phenotyp

91 The most consistent pharmacogenetic associations were observed for the corre

92 atment in neovascular AMD, suggesting strong pharmacogenetic associations with anti-VEGF treatment.

93 standing of pathogenic mechanisms underlying pharmacogenetic associations.

94 warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days.

95 Pharmacogenetic-based dosing was associated with a highe

96 ational Warfarin Pharmacogenetics Consortium pharmacogenetic-based warfarin dosing algorithm (based o

97 ctual disability and provide new genetic and pharmacogenetic biomarkers for neurodevelopmental diseas

98 y provides the first demonstration that host pharmacogenetics can influence therapeutic response in C

99 nes from participants of the Cholesterol and Pharmacogenetics (CAP) simvastatin clinical trial, we fo

100 In the International Warfarin Pharmacogenetic Consortium (IWPC) with 5542 patients, we

101 ding rs7856096 to the International Warfarin Pharmacogenetic Consortium pharmacogenetic dosing algori

102 arin were obtained at International Warfarin Pharmacogenetics Consortium (IWPC) sites and the Univers

103 he recently published International Warfarin Pharmacogenetics Consortium pharmacogenetic-based warfar

104 Rapid advances in pharmacogenetics, continuous decrease in genotyping cost

105 vity, there are relatively little actionable pharmacogenetic data with antiplatelet agents.

106 improving patient management on the basis of pharmacogenetic data.

107 parameters, drug interaction parameters, and pharmacogenetics data have been unevenly collected in di

108 g these barriers to routine incorporation of pharmacogenetics data into clinical care.

109 Here application of a pharmacogenetic deactivation technique enabled us to inv

110 Moreover, few studies use pharmacogenetic designs that permit testing of genotype

111 Thus, NUDT15 is a pharmacogenetic determinant for thiopurine-induced leuko

112 m, and are largely independent of, the major pharmacogenetic determinants of rosuvastatin-induced LDL

113 eagents and has a great potential for future pharmacogenetic diagnostics and therapy.

114 cues, personality traits, neurochemical and pharmacogenetic differences.

115 Ca(2+) channel (CaV1.1 R174W) linked to the pharmacogenetic disorder malignant hyperthermia.

116 gnant hyperthermia (MH) is potentially fatal pharmacogenetic disorder of skeletal muscle caused by in

117 Malignant hyperthermia is a pharmacogenetic disorder typically triggered by potent i

118 national Warfarin Pharmacogenetic Consortium pharmacogenetic dosing algorithm resulted in a 5.8 mg/we

119 Incorporation of this variant into pharmacogenetic dosing algorithms could improve warfarin

120 These findings may have an important pharmacogenetic effect on the development of new PAR ant

121 tion of platelet PAR1 function, but a strong pharmacogenetic effect was observed with the PAR4-specif

122 in the complement factor H (CFH) gene have a pharmacogenetics effect on the anti-vascular endothelial

123 tive of this study is to test the naltrexone pharmacogenetic effects of the Asn40Asp SNP in a sample

124 We also examined pharmacogenetic effects on cognition in the context of a

125 We found pharmacogenetic evidence for a role of 5-HT in mediating

126 Thus, pharmacogenetic evidence suggests that increased 5-HT le

127 Abcb5 alleles are pharmacogenetic factors that affect susceptibility to HI

128 ERN and error positivity were unaffected by pharmacogenetic factors, but ERN was decoupled from beha

129 The pharmacogenetic findings also implicate the kainate rece

130 ch for PD and highlight the applicability of pharmacogenetics for enhancing cellular signaling in rep

131 Using pharmacogenetic gain- and loss-of-function studies, we f

132 Pharmacogenetics genetically re-engineers neurons to pro

133 With its particular relevance to pharmacogenetic GWAS, SurvivalGWAS_SV will aid in the id

134 RECENT FINDINGS: Evidence now suggests that pharmacogenetics has a role in the effects of analgesic,

135 Since its first description, the field of pharmacogenetics has expanded to study a broad range of

136 Pharmacogenetics has led to the identification of severa

137 oncology, systematic application of efficacy pharmacogenetics has not been integrated into drug disco

138 Pharmacogenetics has offered compelling evidence toward

139 The third area, pharmacogenetics, has utility for some therapies today.

140 ic cells and hosts (eg, pharmacokinetics and pharmacogenetics) have pushed the cure rate of childhood

141 integration of research on neuroimaging and pharmacogenetics holds promise for improving treatment f

142 cogenomics Research Network and the Clinical Pharmacogenetics Implementation Consortium are partnersh

143 ical-subcortical networks in humans, and the pharmacogenetic implications of dopamine-related genes o

144 define the role of clopidogrel and warfarin pharmacogenetics in clinical practice.

145 cal trials, and ongoing efforts to implement pharmacogenetics in clinical practice.

146 Using optogenetics and pharmacogenetics in combination with in vivo and in vitr

147 ew Orleans in October 2012, Optogenetics and Pharmacogenetics in Neuronal Function and Dysfunction, b

148 drug pharmacokinetics, pharmacodynamics, and pharmacogenetics in view of the absence of easily measur

149 Pharmacogenetics in warfarin clinical trials have failed

150 ement strategies based on modifier genes, to pharmacogenetics, in which individual genetic informatio

151 Pharmacogenetic inactivation of FosB-expressing neuron e

152 In this article, we provide an overview of pharmacogenetics, including pharmacokinetics (PK), pharm

153 tandardized dose escalation, and to evaluate pharmacogenetics influences on PK and PD parameters.

154 Pharmacogenetic inhibition of C1 neurons bilaterally res

155 We investigated the pharmacogenetic interaction between A118G variation and

156 This study demonstrates a significant pharmacogenetic interaction between anti-IL-4 receptor a

157 evidence as to whether there is any specific pharmacogenetic interaction with dalcetrapib.

158 e largest study to date evaluating the ADCY9 pharmacogenetic interaction.

159 nconsistent, suggesting the possibility of a pharmacogenetic interaction.

160 t effects of OPRM1 allelic variation, or for pharmacogenetic interactions between genotype and drug t

161 nctional variants on schizophrenia risk, and pharmacogenetic interactions of AKT1 with the effects on

162 In the first pharmacogenetic investigation of the efficacy of varenic

163 This is the first large pharmacogenetic investigation of the inflammatory IL-4/I

164 rs of ICS response by conducting the largest pharmacogenetic investigation to date in 2672 ICS-treate

165 A synthesis of opto- and pharmacogenetics is beginning to reveal how various inte

166 Pharmacogenetics is being used to develop personalized t

167 Pharmacogenetics is one example of how gene-environment

168 rare variants to detect and replicate novel pharmacogenetic loci.

169 on studies (GWAS) can rapidly identify novel pharmacogenetic loci.

170 ciation has identified the T gene as a novel pharmacogenetic locus for inhaled corticosteroid respons

171 let cells undergoing developmental/metabolic/pharmacogenetic manipulation in vivo and may facilitate

172 We show that pharmacogenetic manipulation of PFC-SERT+ neuron activit

173 Pharmacogenetic manipulation revealed the individual con

174 rkers for these neurons, and optogenetic and pharmacogenetic manipulations demonstrate that several p

175 Our study discovered novel pharmacogenetic markers and provided detailed insight in

176 atistically significant associations between pharmacogenetic markers and treatment response.

177 interest, our finding may aid in developing pharmacogenetic markers for ADHD.

178 Three principle classes of pharmacogenetic markers have emerged: 1) pharmacokinetic

179 Pharmacogenetics may help physicians deliver individuali

180 variants for monitoring treatment response (pharmacogenetics) may usher in a new era of personalized

181 Here we perform a pharmacogenetic meta-analysis of genome-wide association

182 Opto- and pharmacogenetic methods have played an important role in

183 Using pharmacogenetic methods to conditionally ablate adult ne

184 these results indicate that a comprehensive pharmacogenetic model integrating NUDT15 variants may in

185 ress and inhibition of neurogenesis in a rat pharmacogenetic model.

186 electively inhibiting these neurons with the pharmacogenetic neuromodulator hM4D.

187 II- study (n = 745, age: 8-21, USA) and the Pharmacogenetics of adrenal suppression cohort (n = 391,

188 atric Asthma Gene Environment Study, and the Pharmacogenetics of Adrenal Suppression with Inhaled Ste

189 tcomes pediatric participants (n = 100), and Pharmacogenetics of Asthma Medication in Children: Medic

190 med a meta-analysis of three cohort studies: Pharmacogenetics of Asthma Medication in Children: Medic

191 In conclusion, pharmacogenetics of CFH Y402H polymorphism may play a ro

192 rge transfusion requirements and the complex pharmacogenetics of clopidogrel may have played a role.

193 will discuss the most recent developments in pharmacogenetics of commonly used perioperative medicati

194 stigated the population pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected

195 eliminary results of this pilot study on the pharmacogenetics of FcgammaR and biological therapy in p

196 We summarize recent progress in the pharmacogenetics of IBD with respect to partitioning pat

197 The pharmacogenetics of methotrexate (MTX) was investigated

198 sting roles in chemotherapy disposition, the pharmacogenetics of OATPs in cancer therapy, and OATP ov

199 dependence; however, less is known about the pharmacogenetics of smoking cessation.

200 They also inform the pharmacogenetics of statin treatment by demonstrating th

201 We utilized two cohorts to study pharmacogenetics of weight gain following switch from ef

202 to describe what has heretofore been called pharmacogenetics or chemicogenetics.

203 plicated by acute ketamine administration or pharmacogenetic parvalbumin-interneuron suppression.

204 ic ligand--GPCR pairs (aka DREADDs, RASSLS, 'pharmacogenetics') permits the study of pharmacology usi

205 Pharmacogenetics (PG) could improve dosing efficiency an

206 treatment interaction effect for SNP-sets in Pharmacogenetics (PGx) assessments embedded within rando

207 power for whole exome or genome analysis in Pharmacogenetics (PGx) studies with small sample sizes.

208 Pharmacogenetic/pharmacogenomic (PGx) approaches to psyc

209 ts are likely to have an important effect on pharmacogenetic phenotypes.

210 l implementation of clopidogrel and warfarin pharmacogenetics possible.

211 increasingly apply genomic data analysis to pharmacogenetics, preventive medicine, and patient-targe

212 Pharmacogenetics primarily uses genetic variation to ide

213 that this hyperkinetic disorder has a unique pharmacogenetic profile.

214 3A5 gene is likely to contribute to multiple pharmacogenetic profiles across the continent.

215 s individual susceptibility, prognostic, and pharmacogenetic profiles to maximize the efficacy and mi

216 research settings for causal gene discovery, pharmacogenetic purposes, and gene-gene and gene-environ

217 ight deprivation blocks ODP and, conversely, pharmacogenetic reduction of PV cell firing rates can ex

218 ton magnetic resonance spectroscopy data and pharmacogenetic response to stimulant medication.

219 treated subjects, demonstrating a successful pharmacogenetic screen in MS.

220 This has led to the development of pharmacogenetic screening tests, such as HLA-B*57:01 in

221 In the realm of cardiovascular pharmacogenetics, significant advances have identified m

222 of optical activation and cell type-specific pharmacogenetic silencing in vitro, we found that dendri

223 on cell-type-specific optical activation and pharmacogenetic silencing in vitro, we show that tempora

224 Accordingly, pharmacogenetic silencing of V1 SST(+) interneurons full

225 Here, using optogenetic activation and pharmacogenetic silencing, we found that type 6 bipolar

226 an ancestry who participated in one of three pharmacogenetic smoking cessation clinical trials and we

227 Moreover, optogenetic as well as pharmacogenetic specific activation of the vHipp-mPFC pa

228 rocyte calcium signaling and is decreased by pharmacogenetic stimulation of astrocytes.

229 ent attenuated these responses to subsequent pharmacogenetic stimulation, similar to attenuation of t

230 geneity to this drug class, and may inform a pharmacogenetic strategy for a more effective use of PDE

231 Here, we used a pharmacogenetic strategy to decrease mediodorsal thalami

232 o develop the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline.

233 was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Dr

234 Pharmacogenetic studies aiming to personalize the treatm

235 to improve the transparency of reporting of pharmacogenetic studies and also to facilitate the condu

236 To date, pharmacogenetic studies have been primarily performed in

237 Importance: Previous pharmacogenetic studies have shown the prognostic impact

238 his assay may be useful to complement future pharmacogenetic studies in asthma.

239 NP-drug response association dataset for 650 pharmacogenetic studies involving 257 drugs in this upda

240 er, performing robust synthesis of data from pharmacogenetic studies is often challenging because of

241 Pharmacogenetic studies of admixed ethnic groups have be

242 currently no guideline for the reporting of pharmacogenetic studies that has been developed using a

243 nally, the authors discuss unique aspects of pharmacogenetic studies that may distinguish them from s

244 Prior pharmacogenetic studies usually measure exposure via sin

245 Additional, larger pharmacogenetic studies would help to validate these res

246 s: in vivo pharmacokinetics studies, in vivo pharmacogenetic studies, in vivo drug interaction studie

247 Concerning pharmacogenetic studies, no association was found for th

248 be clearly defined and justified, because in pharmacogenetic studies, there may be a greater number o

249 ed populations, which can be used for future pharmacogenetic studies.

250 here to the STROPS guideline when publishing pharmacogenetic studies.

251 ance of maximizing adherence to treatment in pharmacogenetic studies.

252 Pharmacogenetics studies are the platform for discoverin

253 rom non-responders via genetic predictors in pharmacogenetics studies have not met their anticipated

254 these findings demonstrate the importance of pharmacogenetics studies in veterinary species and sugge

255 This pharmacogenetic study evaluated the impact of high-risk

256 ant that samples be collected and stored for pharmacogenetic study in future clinical trials.

257 mine treatment in a prospective double-blind pharmacogenetics study in first-generation Mexican Ameri

258 This is the largest and most comprehensive pharmacogenetics study to date examining clinical respon

259 nce effects of sex in the Cardiovascular and Pharmacogenetics study.

260 Design, Setting, and Participants: Pharmacogenetic substudy of 1545 patients who participat

261 t are particularly important in the field of pharmacogenetics, such as the drug regimen of interest a

262 ity to HIT, but it is likely that additional pharmacogenetic susceptibility factors will be discovere

263 encephalogram (EEG) power spectrum using the pharmacogenetic technique, the 'designer receptors exclu

264 Here we used pharmacogenetic techniques to show a causal relation bet

265 s to feeding behaviour using optogenetic and pharmacogenetic techniques.

266 clinical CYP2C19 genotyping implementation, pharmacogenetic test results significantly influenced an

267 hose taking clozapine and its potential as a pharmacogenetic test, dependent on the outcome of additi

268 ghlight which variants and in which contexts pharmacogenetic testing can be implemented by practicing

269 Pharmacogenetic testing combined with monitoring of hair

270 ng may be beneficial, the data today support pharmacogenetic testing for certain variants on an indiv

271 In contrast, pharmacogenetic testing for HLA-B*1502 before carbamazep

272 One blood sample was collected for pharmacogenetic testing from each patient who elected to

273 TPMT pharmacogenetic testing identifies only 25% of at-risk p

274 le discusses the current clinical utility of pharmacogenetic testing in the context of a patient who

275 ical trials will determine if routine use of pharmacogenetic testing may be beneficial, the data toda

276 tes that they stand to benefit the most from pharmacogenetic testing.

277 ves for translating clopidogrel and warfarin pharmacogenetic tests to clinical practice.

278 Pharmacogenetics, though presently confined to the asses

279 search into the role of pharmacokinetics and pharmacogenetics to guide appropriate dosing of obese pa

280 typic screen can be coupled with current DNA pharmacogenetics to identify the ideal therapeutic agent

281 extension of previous studies of naltrexone pharmacogenetics to individuals of Asian descent, an eth

282 ngs, two-photon microscopy, optogenetics and pharmacogenetics to show how repeated cocaine exposure a

283 olecular genetics along with optogenetic and pharmacogenetic tools for perturbing neuron function hav

284 Anatomic and pharmacogenetic tools were used to identify the pathways

285 etically encoded anatomical, optogenetic and pharmacogenetic tools, we demonstrate that activation of

286 ls represent a promising novel target in the pharmacogenetic treatment of alcohol and drug addiction.

287 ogy of the disease could help development of pharmacogenetic treatments.

288 vergent findings reported by recent warfarin pharmacogenetic trials.

289 examine the association between clinical and pharmacogenetic variables and statin concentrations in p

290 ative or opiate doses and pharmacokinetic or pharmacogenetic variables, such as drug plasma levels (e

291 1-75.9) of participants carried at least one pharmacogenetic variant of cardiovascular relevance, the

292 ne uncertain variants in cancer genes (98%), pharmacogenetic variants (89%), and recessive carrier mu

293 to review the association data for the major pharmacogenetic variants associated with commonly used c

294 perturbation enables identification of true pharmacogenetic variants.

295 is table may potentially increase the use of pharmacogenetic warfarin dosing in clinical practice; ho

296 Using transgenic mice, optogenetics, and pharmacogenetics, we studied the role of astrocytes on t

297 gly popular, predominantly in the context of pharmacogenetics, where the survival endpoint could be d

298 Ultimately, pharmacogenetics will give providers the options for imp

299 Future utility for pharmacogenetics will wax or wane depending on the natur

300 Optogenetics with microbial opsin genes, and pharmacogenetics with designer receptors, represent pote